Kate Goodwin is a Life Sciences Writer at BioSpace. She covers a range of topics including medicine and healthcare, alternative medicine, and the healthcare system, with a particular focus on the intersection of finance and trading within the life sciences sector. Kate's work has been featured in BioSpace and ArchitectureAU.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Kate's coverage focuses on the healthcare and pharmaceutical industry, particularly biotechnology, pharmaceuticals, clinical trials, FDA approval processes, and investment within the sector. For effective outreach to her, consider providing data-driven insights or press releases related to groundbreaking advancements in biotech or pharmaceutical companies' developments.
As Kate's articles often cite data and rely heavily on press releases for information, she may be interested in receiving pitches that provide exclusive access to company announcements or detailed analysis of research findings from within the healthcare and pharmaceutical sectors.
Kate does not seem to have a specific geographic focus but instead covers international developments within the healthcare and pharmaceutical industries. Therefore, sources with global perspectives or those involved in cross-border collaborations could be appealing to her.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Photys is eligible for up to $186 million from Novo Nordisk for its PHICS small molecules that pair a kinase to a disease-causing protein for phosphorylation.
BioArctic received $100 million upfront with another $1.25 billion in potential milestone payments on the line for two pyroglutamate-amyloid-beta antibodies.
Galectin's shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint for its Phase IIb/III trial for patients with a type of liver cirrhosis.
The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in combination with diet and exercise.
By: Kate Goodwin
Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck's Winrevair and the FDA's greenlight for an injectable formulation of BMS's cancer blockbuster.
Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular benefits in the world's fastest-growing drug class.
Research has shown remnant cholesterol is a significant factor in cardiovascular disease risk.
An FDA committee's September 2024 vote to limit the use of Merck's Keytruda and BMS' Opdivo in stomach and esophageal cancers based on PD-L1 expression levels reflects an emerging trend that leverages ever-maturing datasets.
The FDA accepted Biogen and Eisai’s BLA for a subcutaneous administration of the anti-amyloid antibody Monday as the partners await the regulator’s decision on a new intravenous regimen following an underwhelming launch riddled with coverage and accessibility barriers.
Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, bispecifics and more contributing to multifaceted regimens unique to each patient’s needs.
(833) 317-6278 
